Physician profile
Steele E Summers
NPI 1437546041
$3,211.89
in general payments reported to CMS, 2019-2025
22 companies · $830 in 2025
The $830 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $475 · 2022: $923 · 2023: $399 · 2024: $585 · 2025: $830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,680 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,680.31 |
| Education | $133.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $599.94 | 2021-2025 | Airsupra, Breztri, Tezspire |
| Genzyme Corporation | $537.40 | 2021-2025 | |
| Glaxosmithkline, LLC. | $529.98 | 2021-2025 | Nucala, Trelegy Ellipta |
| Amgen INC. | $244.77 | 2022-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $223.06 | 2021-2025 | Dupixent |
| Pfizer INC. | $217.18 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $136.48 | 2024-2025 | |
| Optinose US, INC. | $129.67 | 2022 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2025 | |
| Csl Behring | $93.44 | 2021-2025 | Haegarda, Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $69.62 | 2022-2024 | Eohilia |
| Blueprint Medicines Corporation | $61.93 | 2022-2023 | Ayvakit |
| Teva Pharmaceuticals USA, INC. | $55.24 | 2021-2022 | |
| Grifols USA, LLC | $43.85 | 2022 | |
| Kaleo, INC. | $35.53 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $27.83 | 2021-2023 | |
| Ars Pharmaceuticals Operations, INC. | $24.27 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $19.18 | 2023 | Orladeyo |
| Octapharma USA, INC. | $18.51 | 2023 | Cutaquig |
| Pharming Healthcare, INC. | $18.11 | 2024 | Ruconest |
| Leo Pharma INC. | $15.08 | 2022 | |
| Genentech USA, INC. | $10.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steele Summers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.